- $725.99m
- $674.90m
- $183.88m
Brief: Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Geron Corp reports results for the quarter ended June 30 - Earnings Summary
Brief: Geron Appoints Harout Semerjian As President And Chief Executive Officer
Brief: Geron Q2 EPS USD -0.02
Brief: Geron Corp reports inducement grants under Nasdaq listing rule
Geron Corp reports results for the quarter ended March 31 - Earnings Summary
Brief: Geron Q1 EPS USD -0.03 Vs. IBES Estimate USD -0.04
Brief: Geron reports inducement grants under Nasdaq listing rule 5635(C)(4)
Brief: Geron Announces EC Approval For RYTELO To Treat Transfusion-Dependent Anemia
Brief: Geron Corporation Announces Departure Of CEO
U.S. RESEARCH ROUNDUP-Abbvie, Freeport-Mcmoran, Goldman Sachs
Geron Corp reports results for the quarter ended December 31 - Earnings Summary
Brief: Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese Adults
Geron Corp reports results for the quarter ended in September 30 - Earnings Summary
Brief: Geron Corp Reports Q3 2024 Financial Results And Recent Business Highlights
Brief: Geron Corp Announces Up To $375 Mln In Funding With Royalty Pharma And Pharmakon Advisors